“The quarter illustrates the benefit of our balanced end market and geographic diversification while reinforcing our outlook for accelerating revenue and earnings growth in the second half and beyond.”

In context

“on the call today. We delivered a solid second quarter with better-than-expected revenue, earnings, and cash flow. We were particularly pleased to see an acceleration in core growth versus the first quarter, driven by good commercial execution, recent innovation, and recovery in our end market. Our life sciences businesses delivered their strongest quarter in several years. Diagnostics continued to perform well. While customer project timing impacted bioprocessing revenue, underlying order trends remained robust. Improved growth across our portfolio, paired with benefits from our recent productivity initiatives, helped drive high single-digit earnings growth. This strong execution and the earlier-than-expected close of Masimo enables us to again raise our full year adjusted EPS guidance. The quarter illustrates the benefit of our balanced end market and geographic diversification while reinforcing our outlook for accelerating revenue and earnings growth in the second half and beyond. Across our end markets, we saw encouraging signs of stabilization and improvement. Demand from large pharma and biopharma customers remained healthy, while improved biotech funding supported improved funnel and order activity. Academic and government markets have largely stabilized, while clinical and applied remained consistent sources of strength across the portfolio. As we look to the second half of 2026 and beyond, we're encouraged by the momentum across our businesses and the long-term value creation opportunities ahead for us. We're well-positioned in attractive end markets with strong secular growth drivers. Our capital deployment flywheel is active, supported by significant balance sheet optionality. The Danaher Business System and our team are powerful differentiators, helping us”